Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1226 in Hospitalized Moderate COVID-19 Pneumonia
NCT04738136Phase 2Suspended
- Sponsor
- SolAeroMed
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of S-1226 in COVID-19 pneumonia, bronchiolitis, sponsored by SolAeroMed. Started Sep 2021; status: suspended.
02
Drugs
S-1226
03
Conditions
COVID-19 pneumoniabronchiolitis
Beyond the preview
Go deeper on NCT04738136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04738136.